Detection of complement activation using monoclonal antibodies against C3d
Authors:
- Joshua M. ThurmanJTJoshua M. Thurman
- Liudmila KulikLKLiudmila Kulik
- Heather OrthHOHeather Orth
- Maria WongMWMaria Wong
- Brandon RennerBRBrandon Renner
- Siranush A. SargsyanSSSiranush A. Sargsyan
- Lynne M. MitchellLMLynne M. Mitchell
- Dennis E. HourcadeDHDennis E. Hourcade
- Jonathan P. HannanJHJonathan P. Hannan
- James M. KovacsJKJames M. Kovacs
- Beth CoughlinBCBeth Coughlin
- Alex S. WoodellAWAlex S. Woodell
- 24 April 2013
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (5) , 2218-2230
Abstract
During complement activation the C3 protein is cleaved, and C3 activation fragments are covalently fixed to tissues. Tissue-bound C3 fragments are a durable biomarker of tissue inflammation, and these fragments have been exploited as addressable binding ligands for targeted therapeutics and diagnostic agents. We have generated cross-reactive murine monoclonal antibodies against human and mouse C3d, the final C3 degradation fragment generated during complement activation. We developed 3 monoclonal antibodies (3d8b, 3d9a, and 3d29) that preferentially bind to the iC3b, C3dg, and C3d fragments in solution, but do not bind to intact C3 or C3b. The same 3 clones also bind to tissue-bound C3 activation fragments when injected systemically. Using mouse models of renal and ocular disease, we confirmed that, following systemic injection, the antibodies accumulated at sites of C3 fragment deposition within the glomerulus, the renal tubulointerstitium, and the posterior pole of the eye. To detect antibodies bound within the eye, we used optical imaging and observed accumulation of the antibodies within retinal lesions in a model of choroidal neovascularization (CNV). Our results demonstrate that imaging methods that use these antibodies may provide a sensitive means of detecting and monitoring complement activation–associated tissue inflammation.Keywords
This publication has 47 references indexed in Scilit:
- Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritisKidney International, 2012
- Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injuryKidney International, 2011
- The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr miceArthritis & Rheumatism, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Renal Inflammation: Targeted Iron Oxide Nanoparticles for Molecular MR Imaging in MiceRadiology, 2010
- A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2009
- Structure of complement fragment C3b–factor H and implications for host protection by complement regulatorsNature Immunology, 2009
- Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phaseMolecular Immunology, 2009
- Molecular Basis of the Interaction between Complement Receptor Type 2 (CR2/CD21) and Epstein-Barr Virus Glycoprotein gp350Journal of Virology, 2008
- Factor I is required for the development of membranoproliferative glomerulonephritis in factor H–deficient miceJournal of Clinical Investigation, 2008